Company: IMNN
Filing Date: 2025-05-12
Form Type: 10-Q
Source: 0001641172-25-009572
Chunk: 44

Company: Imunon, Inc.
Filing Date: 2025-05-12
Form: 10-Q
Item: Part I, Item 2
Chunk 44
---
The following discussion and analysis of our financial
condition and results of operations This discussion contains forward-looking statements that involve risks and uncertainties. Our actual
results may differ materially from those discussed in forward-looking statements. Factors that might cause a difference include, but are
not limited to, those discussed above under “Cautionary Note Regarding Forward-Looking Statements,” and in Item 1A. Risk factors
in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024.

Overview

Imunon is a clinical-stage biotechnology company focused
on advancing a portfolio of innovative treatments that harness the body’s natural mechanisms with the aim to generate safe, effective
and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. Imunon
is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas®, is developed for the coding of proteins
and cytokines in the treatment of solid tumors where an immunological approach is deemed promising. The second modality, PlaCCine®,
is developed for the coding of viral antigens that can elicit a strong immunological response. This technology may represent a promising
platform for the development of vaccines in infectious diseases.

The Company’s lead clinical program, IMNN-001,
is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed Phase II clinical development studies.
IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12
and interferon gamma, at the tumor site. Additionally, the Company has entered into a first-in-human study of its COVID-19 booster vaccine
(IMNN-101). We will continue to leverage these modalities and to advance the technological frontier of plasmid DNA to better serve patients
with difficult-to-treat conditions.

Technology Platform

Imunon’s technology platform is optimized for
the delivery of DNA and mRNA therapeutics via synthetic non-viral carriers and is capable of providing cell transfection for double-stranded
DNA plasmids and large therapeutic RNA segments such as mRNA. There are two components to the system, a backbone with plasmid DNA or mRNA
payload encoding therapeutic proteins, or pathogen antigens or tumor associated antigens or cancer neoantigens and a delivery system.
The delivery system is designed to protect the DNA or mRNA from degradation and promote trafficking into cells and through intr